Research Transparency in 59 Disciplines of Clinical Medicine: A Meta-Research Study

- 4 Ahmad Sofi-Mahmudi*¹⁻³, ORCiD: 0000-0001-6829-0823
- 5 Eero Raittio^{4,5}, ORCiD: 0000-0002-9258-9355

1

2

3

12

- 6 Sergio E. Uribe⁶⁻⁸, ORCiD: 0000-0003-0684-2025
- 7 Sahar Khademioore², ORCiD: 0000-0002-3025-0006
- 8 Dena Zeraatkar^{1,2}, ORCiD: 0000-0003-4287-0541
- 9 Lawrence Mbuagbaw^{1,2,9–11}, ORCiD: 0000-0001-5855-5461
- 10 Lex M. Bouter^{12,13}, ORCiD: 0000-0002-2659-5482
- 11 Karen A. Robinson¹⁴, ORCiD: 0000-0003-1021-7820
- 13 1 National Pain Centre, Department of Anesthesia, McMaster University, Hamilton, ON, Canada.
- 2 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
- 15 3 Seqiz Health Network, Kurdistan University of Medical Sciences, Seqiz, Kurdistan.
- 4 Institute of Dentistry, University of Eastern Finland, Kuopio, Finland.
- 17 5 Department of Dentistry and Oral Health, Aarhus University, Aarhus, Denmark.
- 6 Department of Conservative Dentistry and Oral Health, Riga Stradins University, Riga, Latvia.
- 19 7 Faculty of Dentistry, Universidad de Valparaíso, Valparaíso, Chile.
- 20 8 Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, Riga, Latvia.
- 9 Biostatistics Unit, Father Sean O'Sullivan Research Centre, Hamilton, ON, Canada.
- 22 10 Centre for Development of Best Practices in Health, Yaoundé Central Hospital, Yaoundé, Cameroon.
- 23 11 Department of Global Health, Stellenbosch University, Cape Town, South Africa.
- 24 **12** Amsterdam Universities Medical Center, Amsterdam, the Netherlands.
- 25 13 Vrije Universiteit, Amsterdam, the Netherlands.
- 26 14 Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD, USA.

- 29 Corresponding author: Ahmad Sofi-Mahmudi; Address: MDCL-2109, 1280 Main Street West,
- 30 Hamilton, ON L8S 4K1, Canada; **Telephone**: +1 (905) 525-9140 ext. 22743; **Email**:
- 31 <u>sofima@mcmaster.ca</u>; <u>a.sofimahmudi@gmail.com</u>.

34

- 33 **Conflict of interest disclosure:** The authors have no conflicts of interest to disclose.
- 35 **Funding disclosure:** This study did not receive any funding.
- 37 **Acknowledgments:** The computational analyses were performed on servers provided by UEF
- 38 Bioinformatics Center, University of Eastern Finland, Finland. Uribe was supported by the European
- 39 Union's Horizon 2020 grant 857287 for the Baltic Biomaterials Centre of Excellence, Headquarters at
- 40 Riga Technical University, Riga, Latvia.

Abstract

- 42 **Background:** Transparency in health research is crucial as it allows for the scrutiny and replication of
- findings, fosters confidence in scientific outcomes, and ultimately contributes to the advancement of
- 44 knowledge and the betterment of society.
- 45 **Aim:** We aimed to assess five transparency practices in scientific publications (data availability, code
- 46 availability, protocol registration, conflicts of interest (COI) and funding disclosures) from open-access
- 47 articles published in medical journals.
- 48 **Methods:** We searched and exported all open-access articles from Science Citation Index Expanded
- 49 (SCIE)-indexed journals through the Europe PubMed Central database published until March 16, 2024.
- 50 Basic journal- and article-related information was retrieved from the database. We then assessed five
- 51 transparency practices in the articles using the rtransparent package in R.
- Results: The analysis included 2,002,955 open-access articles from SCIE-indexed medical journals
- 53 (open-access percentage=59.0%). Of these, 87.5% (95% CI: 87.4%-87.5%) disclosed COI and 80.1%
- 54 (95% CI: 80.0%-80.1%) disclosed funding. Protocol registration was declared in 6.6% (95% CI: 6.6%-
- 55 6.6%), data sharing in 7.6% (95% CI: 7.6%-7.6%), and code sharing in 1.4% (95% CI: 1.4%-1.4%) of
- 56 the articles. More than 76.0% declared at least two transparency practices, while all five practices were
- declared in less than 0.02%. The data showed an increasing trend in all transparency practices since the
- late 2000s. Articles published in journals with higher impact factors and articles receiving more
- 59 citations had increased odds of COI and funding disclosures, as well as data and code sharing. There
- were notable differences in transparency practices across the disciplines.
- 61 **Conclusion:** While most articles had COI and funding disclosures, adherence to other transparency
- 62 practices was grossly insufficient. To increase protocol registration, data, and code sharing, much
- stronger incentives and mandates are needed from all stakeholders.
- 64 Keywords: Conflict of Interest; Code Sharing, Data Sharing; Funding Disclosure, Information
- Dissemination, Meta-research, Open Science, Protocol Registration.

Background

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Recent recognition of health research transparency, essential for accountability, has resulted in stringent disclosure requirements by academic, medical institutions, and voluntary industry and publisher policies (1,2). Although global regulatory bodies, funding agencies, and ethics boards supervise medical research, transparency and disclosure practices are still inconsistent and incomplete (3,4). Research conducted by industry, academia, or their collaboration equally has deficiencies in transparency (2,5). Despite publishers' policies, ethical mandates, and mission statements (6), academic medical centers show poor performance and significant variation in disseminating clinical trial results following transparency practices (7). Transparency in research is pivotal for accountability and trust in results and upholds the ethical responsibilities of researchers, editors, publishers, and funders (8–12). Inefficient use of primarily public or non-profit research funding significantly disadvantages patients and society. Therefore, it is crucial to continuously improve, investigate and monitor research transparency. Key indicators of research transparency include data sharing, code sharing, disclosures of conflicts of interest, funding acknowledgments, and protocol registration (13). Data sharing is more common in non-COVID-19 articles (12%) than in COVID-19 studies (4%) (14). A systematic review of 105 meta-research studies, analyzing 2,121,580 articles across 31 specialties, uncovered substantial transparency challenges (15). Issues include low declared (8%) and actual (2%) public data availability, minimal public code sharing (<0.5%), and inconsistent journal data-sharing policy adherence. This review also noted discrepancies between declared and actual data sharing practices and challenges in privately obtaining data and code from authors (15). These findings highlight the pressing need to enhance transparency, particularly during public health crises.

Our meta-research study assessed research transparency regarding data and code sharing, conflict of interest (COI) and funding disclosure, and protocol registration across all medical specialties. Through programmatic and comprehensive analysis, we aimed to identify patterns and areas most needing improvement.

Methods

93 The protocol of this descriptive study was published on the Open Science Framework (OSF) website

(<u>https://doi.org/10.17605/OSF.IO/J57BG</u>). All the code and data associated with the study were shared

through both its OSF repository (https://osf.io/zbc6p/) and GitHub (https://github.com/choxos/medical-displayed-repository)

transparency). To ensure transparency and facilitate the reproducibility of our analyses, a PDF

document containing the codes and corresponding outputs is provided in Appendix 1.

Data sources and study selection

Initially, we searched records within journals listed in the 59 disciplines of the "Clinical Medicine" section in the Science Citation Index Expanded (SCIE) version 2020. This search was performed using the Europe PubMed Central (EPMC) database until February 28, 2022. We updated the search on March 16, 2024. The EPMC database encompasses all records found in PubMed and PubMed Central records and allows automated retrieval of full-texts of EPMC open-access records. Remarkably, what is being called here "EPMC open-access articles" do not include all "open-access" labeled articles (e.g., by the journals/publishers), because some of those articles are still subject to traditional copyright restrictions. Thus, their full texts cannot be accessed via EPMC.

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

Using the *metareadr* package (16), we retrieved the full texts of all identified open-access records in XML format from the EPMC database. Concurrently, we extracted descriptive details for each journal and article, including publisher, publication year, and citations linked to the article and journal, directly from the EPMC database. We only included research articles (PUB TYPE: "research-article") and reviews (PUB TYPE: "review-article" OR PUB TYPE: "systematic-review") for our final analyses. To identify trials, we created a database of trials by searching for articles that had (PUB TYPE: "Randomized Controlled Trial" OR PUB TYPE: "Clinical Trial" OR PUB TYPE: "Clinical Trial, Phase III" OR PUB TYPE: "Clinical Trial, Phase IV") tags as their article type using the europepmc package. Articles in our data set that appeared in the trials database were tagged as trials. Similarly, articles tagged as (PUB TYPE: "review-article" OR PUB TYPE: "systematic-review") were detected as reviews. We used the Scimago Journal & Country Rank 2022 (SJR, https://www.scimagojr.com) to extract the publisher of the journals. **Data extraction and synthesis** We used the *rtransparent* package (17), a validated and automated programmatic tool (13), to identify five transparent practices from the full texts we were able to download from EPMC: Data sharing: The accessibility of data or metadata obtained during a research study, typically through public repositories or inclusion as supplementary materials accompanying the published work.

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Code sharing: The disclosure of computer code or scripts employed for data analysis in 2. research facilitates the replication of results and enables the broader utilization of the study's methodologies. 3. Conflict of interest (COI) disclosures: The public acknowledgment of potential conflicts of interest that could impact the research, commonly presented within a designated publication section. Funding disclosures: The disclosure of the sources of financial support for the research, promoting transparency regarding the possible influence of funding organizations. Protocol registration: The public disclosure of research protocols before conducting a study 5. designed to reduce bias and increase transparency in the research process. The package uses a standardized vocabulary to identify transparency indicators in EPMC XML files. It detects keywords related to COI disclosure, such as "conflicts of interest," "competing interests," or "nothing to disclose," in article section titles or bodies. The tool recognizes all mentions of COI and funding disclosures and treats "nothing to disclose" statements as an indication of transparency, similar to actual conflict disclosures. To assess data and code sharing, the rtransparent tool detects mentions that indicate that they are shared either as supplemental content, in general repositories (e.g., figshare, OSF, GitHub), or in fieldspecific repositories (e.g., dbSNP, ProteomeXchange, GenomeRNAi). Items that state "data available upon request" are not considered data sharing due to the unlikelihood of data acquisition (18). The rtransparent tool demonstrates robust validation, with high sensitivity and specificity for detecting transparency indicators: conflict of interest disclosure (sensitivity 99.2%, specificity 99.5%), funding

disclosure (sensitivity 99.7%, specificity 98.1%), protocol registration (sensitivity 95.5%, specificity

99.7%), data sharing (sensitivity 75.8%, specificity 98.6%), and code sharing (sensitivity 58.7%,

specificity 99.7%) (13).

Data analysis

First, we computed the percentage of articles with full-texts available via EPMC (EPMC open-access records) out of the total number of articles within the database. Alongside providing descriptive statistics for the obtained sample, we reported transparency practices categorized by publication type. We also determined and reported the number of transparency practices that articles with available full-text declared within each publication type, ranging from 0 to 5 practices. Furthermore, we charted differences in transparency practices between 59 distinct clinical medicine disciplines over time. The sensitivity and specificity of the *rtransparent* tool (17) were used to generate 95% confidence intervals (CIs) for the estimates of the transparency practices. We used visual presentation and Pearson's product-moment correlation to analyze the yearly trend in transparency practices. We used logistic regression adjusted by year of publication to test the relationship between transparency indicators and journal impact factor or received citations. We also used a random intercept generalized linear model to investigate the trends of transparency practices among different medical disciplines.

Results

166

167

176

General characteristics

168 As of March 16, 2024, EPMC contained 3,397,155 articles from the SCIE-indexed medical journals in 169 total. Of these, 2,002,955 (59.0%) records had full text available for download. Of the articles, 40,307 170 (2.0%) were published before 2000, 812,146 (40.5%) in the 2010s, and 1,065,770 (53.2%) after 2020. 171 The articles came from 3,458 journals, led by the International Journal of Environmental Research and 172 Public Health (n=59,448, 3.0%), Frontiers in Immunology (n=32,224, 1.6%), and Medicine (Baltimore) 173 (n=28,605, 1.4%). Among 450 publishers, Nature Publishing Group (465,741, 23.3%), 174 Multidisciplinary Digital Publishing Institute (MDPI) (250,360, 12.5%), and Frontiers Media (167,114, 175 8.3%) had the highest number of papers. There were 261,803 (13.1%) reviews and 91,014 (4.5%) trials.

Discipline-specific characteristics

177 On average, 89.2% (SD=8.60%) of the journals had at least one downloadable full-text in EPMC. 178 Oncology (8.9%, n=219,797), Medicine, General & Internal (8.1%, n=199,331), and Medicine, 179 Research & Experimental (7.2%, n=176,858) had the highest number of papers whereas Medicine, 180 Legal (0.1%, n=1.231), Audiology & Speech-language Pathology (0.1%, n=1.571), and Medical Ethics 181 (0.1%, n=2,959) had the lowest. For full-text availability in EPMC, Integrative & Complementary 182 Medicine (88.8%, n=21,468), Tropical Medicine (84.6%, n=32,342), and Medicine, Research & 183 Experimental (75.8%, n=176,858) led, while Substance Abuse (16.2%, n=3,623), Audiology & 184 Speech-language Pathology (16.5%, n=1,571), and Peripheral Vascular Disease (24.8%, n=10,289) had 185 the lowest availability (Appendix 2).

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

Medicine, Research & Experimental (13.7%, n=12,424), Medicine, General & Internal (12.5%, n=11,344), and Oncology (10.1%, n=9,214) had the highest number of trials. The highest number of reviews belonged to Oncology (12.1%, n=31,676), Medicine, General & Internal (11.1%, n=28,982), and Pharmacology & Pharmacy (10.1%, 26,493). Transparency practices overall Of the analyzed full-text articles, 88.8% (95% CI: 88.8%-88.9%) disclosed a COI. Funding disclosures were present in 82.2% (82.1%-82.2%) of articles. Pre-publication registration was mentioned in 7.0% (6.9%-7.0%) and data sharing in 8.0% (8.0%-8.0%) of articles. Code sharing was reported in 1.5% (1.5%-1.5%) (Figure 1A - left). More than 78.3% mentioned at least two transparency indicators, while 0.02% complied with all five. The left-hand side of Figures 1B and 1C show the adherence to transparency practices in reviews and trials. Reviews (92.2%, 92.1%-92.3%) and trials (93.1%, 92.9%-93.2%) had higher COI disclosure than all articles. Trials (88.0%, 87.8%-88.2%) mentioned funding disclosure more often than all articles but reviews less often (77.4%, 77.2%-77.5%). Protocol registration was mentioned in 59.6% (59.3%-60.0%) of the trials whereas reviews (6.5%, 6.5%-6.6%) mentioned preregistration less often compared to all articles. Data and code sharing were less often reported in reviews and trials than in all articles. A visual analysis of the data since the end of the 2000s shows a steady increase in the proportion of articles reporting transparency practices (Figure 1, right). Pearson's product-moment correlation between publication year and transparency practices was highest for funding disclosure (0.716) and lowest for code sharing (0.521). All the *P*-values were <0.001 (Appendix 1).





Figure 1. The proportion of 2,002,955 analyzed articles with transparency practices in total (A) and over time (B).

Articles published in journals with higher impact factors and articles receiving more citations had increased odds of funding disclosures, as well as data and code sharing (Figure 2A). The relationships of the journal impact factor and received citations with the odds of protocol registration were negative

in all articles, and strongly negative in reviews. The relationships of the journal impact factor and received citations were more mixed.

214



219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

Figure 2. Transparency practices in research articles by Journal Impact Factor quintiles (A, lowest quintile, Q1 as the reference), and number of citations to article (B, zero citation as the reference). Odds ratios were adjusted for the year of article publication. Transparency practices by medical disciplines Conflict of Interest Disclosure The highest rates of COI disclosures were found in Rheumatology (98.1%), Primary Health Care (97.4%) and Emergency Medicine (96.8%). On the lower end, Medicine, Legal showed 61.6%, Toxicology 67.5%, and Neuroimaging 71.5% rate of COI disclosures (Appendix 3). The 2010s marked a period of increasing COI disclosures across most medical disciplines (Appendix 4). Funding Disclosure The highest rates of funding disclosure were found in Neuroimaging (94.9%), Materials Science, Biomaterials (94.0%), and Audiology & Speech-language Pathology (93.3%). In contrast, Medical Laboratory Technology reports 60.3%, Andrology 64.7%, and Critical Care Medicine 64.8% (Appendix 3). Funding disclosures, akin to COI disclosures, have shown an overall increase during the 2010s across various disciplines (Appendix 4). **Protocol Registration** Anesthesiology (34.5%) had the highest proportion of articles declaring protocol registration, followed by Rehabilitation (17.2%) and Critical Care Medicine (15.2%). Materials Science, Biomaterials (0.3%), Genetics & Heredity (0.9%), and Virology (1.2%) showed the lowest proportions (Appendix 3).

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

Anesthesiology, for example, has seen a steady increase, reaching up to 40%, contrasting with consistently low rates in disciplines like Immunology and Toxicology (Appendix 4). Data Sharing Data sharing was mentioned most frequently in Genetics & Heredity (37.9%), Neuroimaging (24.7%), and Virology (23.5%), while Surgery, Primary Health Care, and Orthopedics (all 1.6%) showed the lowest rates (Appendix 3). Although there has been an increase in data sharing in certain disciplines, such as Neuroimaging (approximately 80% in 2022), these trends are lower compared to COI and funding disclosures (Appendix 4). **Code Sharing** In code sharing, Neuroimaging (12.4%), Genetics & Heredity (7.6%), and Medical Informatics (6.3%) had the highest rates of code sharing, in contrast to negligible rates in Orthopedics, Nursing, and Integrative & Complementary Medicine (Appendix 3). Code sharing remains relatively low compared to the higher prevalence of COI and funding disclosures, though an increasing trend is observed in specific medical disciplines (Appendix 4). The random intercept generalized linear mixed-effects logistic models examining transparency indicators over time among different disciplines showed the highest random effects variance for code sharing (1.347) and the lowest for funding disclosure (0.345). Full details are available in Appendix 1 and 5.

Discussion

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

Our analyses of over two million full-text articles published in SCIE-indexed medical journals revealed high compliance with COI and funding disclosure in medical research since the early 2010s. However, data sharing, protocol registration, and code sharing remained relatively rare. A recent study highlights the critical role of best practices, such as pre-registration, in research (19). It demonstrates that adherence to these practices correlates with an 86% success rate in replication studies, significantly higher than the 50% success rate observed in some earlier replication efforts. Given the observed low rates of protocol registration, code sharing, and data sharing in our analysis, it is plausible that current research in these disciplines may face challenges in replicability, potentially falling short of the higher success rates associated with rigorous adherence to best practices. To our knowledge, differences in transparency practices across a wide range of medical disciplines have not been studied before in this level of detail. Instead of focusing on a single transparency practice, such as data sharing, within one field of medicine or, e.g., its few highest-impact journals, the applied programmatic approach allowed us to estimate five transparency practices across a high number of studies across the range of medical disciplines (15). Previous research on data and code sharing has often taken a more generalized approach, focusing on overarching trends within the biomedical literature or narrowing their scope to specific disciplines or even individual journals (15). In contrast, our study delved into a detailed analysis, revealing substantial disparities, particularly in protocol registration and data or code sharing. These discrepancies likely mirror variations in research methodologies, reporting standards, publishing norms, peer review processes, and editorial practices prevalent across different medical domains. Conversely, our study indicates that COI and funding disclosures have been relatively prevalent since the mid-2000s. This suggests that achieving a high

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

level of adherence to transparency practices could be attainable with concerted and universally applied efforts that have been behind promoting COI and funding disclosures (20). For instance, journals could adhere to Transparency and Openness Promotion Guidelines and guide authors accordingly (21). Recently, it was shown that it is possible to increase data and code sharing with such efforts, and thus subsequently increase the reproducibility of research substantially (22). Indeed, we believe that protocol registration, data and code sharing would become much more common if they were required for publication, similar to current requirements for COI and funding disclosures. Even though we were able to use a large sample of articles and validated methods to estimate the prevalence of five transparency practices, our study also has some limitations. The analyzed articles represent, to some extent, a biased subset of all medical literature, even though earlier research has shown that there are no clear differences in these five transparency practices between articles with and without available full text in the EPMC (23). The applied methodology has not been validated for the whole time, the original validation covered the years 2015-2019 (13). We cannot be sure that it is equally valid/accurate within each of the 59 medical disciplines, because there may be some systematically different ways of registering protocols and sharing data or code, e.g. via some smaller and thus (uncoded) repositories/platforms. Furthermore, we did not manually evaluate the validity or accuracy of the disclosures, protocols, or data/code availability statements, but other studies have found similar results: these are frequently suboptimal (24,25). That is one reason why we are conducting further research to investigate findability, accessibility, interoperability, and reusability datasets from the articles reporting sharing data (26). In a similar study on COVID-19 research data availability, we found that among 8,015 articles detected by the rtransparent tool as having shared their data in a general repository, 5,700 (71.1%) actually had available data (27). It is also important to note that the articles in our sample included a wide range of research, some of which may not have necessitated

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

using any data or code. Consequently, we acknowledge that achieving a 100% rate in data and code sharing would not be a realistic expectation. For instance, disciplines such as "Medical Ethics" or "Medicine, Legal" may predominantly comprise qualitative research papers, which may not inherently involve creating or utilizing datasets or codes. Instead, in disciplines like "Genetics & Heredity" dataintensive research is likely more common. Additionally, the issue of protocol registration introduces some complexity because there is no consensus regarding the necessity of pre-registration for certain study types, such as explorative (as opposed to hypothesis-testing) or qualitative research. These discrepancies likely drive the observed variations across the 59 distinct medical disciplines. Consequently, it is essential to interpret the results with caution and make comparisons with an understanding of these inherent variations across the diverse spectrum of medical research. Compared to all articles with available full-text in the EPMC database (13), the analyzed subsample of articles from SCIE-indexed medical journals showed higher prevalence of COI and funding disclosures and protocol registration, but equal prevalence data and code-sharing. It seems these disparities primarily stem from historical trends. Specifically, the SCIE-indexed articles exhibited higher levels of transparency practices in earlier years. Interestingly, in 2020, the sample comprising all articles with available full-text in the EPMC database demonstrated greater data and code sharing, but lower adherence to protocol registration, COI disclosures, and funding disclosures when compared to our findings of the SCIE-indexed articles in 2024 (in parenthesis): 15% (11%) for data sharing, 3% (2.5%) for code sharing, 90% (97%) for COI disclosures, 85% (92%) for funding disclosures, and 5% (10%) for protocol registration. Menke et al. have also investigated the presence of protocols and data and code sharing in all articles with full-text in the EPMC database with another automated tool (28). They found a similar constant trend in code sharing that we did. However, they found a more pronounced increase in and higher overall adherence to protocol registration (19% vs. 9%) and data sharing (17%

vs. 9%) in 2020 than our findings indicate, potentially attributable to differences in these automated

methods.

327

328

329

330

331

332

333

334

335

336

337

338

In conclusion, our study reveals that key transparency practices such as data sharing, protocol registration, and especially code sharing continue to be notably scarce in medical research. While adherence to COI and funding disclosures is commendable, the limited adoption of these other crucial transparency practices across diverse medical disciplines remains a significant concern. The recent findings highlighting a high replication success rate with rigorous transparency, underscore the vital need for the universal adoption of such practices (19,22). We urge researchers, journal editors, and policymakers to advance these practices by advocating for the standardization of protocol registration and open data/code sharing across all medical disciplines. Such a collective commitment is essential to enhance the integrity, reliability, and impact of medical research, ultimately benefiting the global health community.

References

- ICMJE. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work
 in Medical Journals [Internet]. International Committee of Medical Journal Editors (ICMJE); 2023.
 Available from: https://www.icmje.org/icmje-recommendations.pdf
- Steinbrook R, Ross JS. "Transparency Reports" on Industry Payments to Physicians and Teaching Hospitals. JAMA. 2012 Mar 14;307(10):1029.
- 34. Tafuri G, Trotta F, Leufkens HGM, Pani L. Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency: Letter to the Editors. Br J Clin Pharmacol. 2013 Apr;75(4):1149–51.
- Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. Hamel MB, editor. N Engl J Med. 2015 Jan 15;372(3):279–86.
- Collier R. Transparency poor in academic medical research. Can Med Assoc J. 2016 May
 17;188(8):E133–E133.

- Dal-Ré R. Are the Most Prestigious Medical Journals Transparent Enough? Trends Pharmacol Sci.
 2016 Sep;37(9):731–3.
- 7. Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ. 2016 Feb 17;i637.
- 8. Needleman I, Moher D, Altman DG, Schulz KF, Moles DR, Worthington H. Improving the Clarity and Transparency of Reporting Health Research: a Shared Obligation and Responsibility. J Dent Res. 2008 Oct;87(10):894–5.
- 9. Nicholls SG, Langan SM, Benchimol EI, Moher D. Reporting transparency: making the ethical mandate explicit. BMC Med. 2016 Dec;14(1):44, s12916-016-0587–5.
- 10. Munafò MR, Nosek BA, Bishop DVM, Button KS, Chambers CD, Percie du Sert N, et al. A manifesto for reproducible science. Nat Hum Behav [Internet]. 2017 Jan;1(1). Available from: http://dx.doi.org/10.1038/s41562-016-0021
- 11. Besançon L, Peiffer-Smadja N, Segalas C, Jiang H, Masuzzo P, Smout C, et al. Open science saves
 lives: lessons from the COVID-19 pandemic. BMC Med Res Methodol [Internet]. 2021 Jun
 5;21(1). Available from: http://dx.doi.org/10.1186/s12874-021-01304-y
- 12. Bosma CM, Granger AM. Sharing is caring: Ethical implications of transparent research in psychology. Am Psychol. 2022 May;77(4):565–75.
- 370 13. Serghiou S, Contopoulos-Ioannidis DG, Boyack KW, Riedel N, Wallach JD, Ioannidis JPA.
 371 Assessment of transparency indicators across the biomedical literature: How open is open? Bero L,
 372 editor. PLOS Biol. 2021 Mar 1;19(3):e3001107.
- 373 14. Zavalis EA, Contopoulos-Ioannidis DG, Ioannidis JPA. Transparency in Infectious Disease
 374 Research: Meta-research Survey of Specialty Journals. J Infect Dis. 2023 Aug 11;228(3):227–34.
- 15. Hamilton DG, Hong K, Fraser H, Rowhani-Farid A, Fidler F, Page MJ. Prevalence and predictors
 of data and code sharing in the medical and health sciences: systematic review with meta-analysis
 of individual participant data. BMJ. 2023 Jul 11;e075767.
- 378 16. Serghiou S. Metareadr: Downloads data often needed for meta-research [Internet]. 2022. Available from: https://github.com/serghiou/metareadr
- 380 17. Serghiou S. rtransparent: Identifies indicators of transparency. 2021; Available from: http://github.com/serghiou/rtransparent
- 18. Gabelica M, Bojčić R, Puljak L. Many researchers were not compliant with their published data sharing statement: a mixed-methods study. J Clin Epidemiol. 2022 Oct;150:33–41.
- 19. Protzko J, Krosnick J, Nelson L, Nosek BA, Axt J, Berent M, et al. High replicability of newly discovered social-behavioural findings is achievable. Nat Hum Behav [Internet]. 2023 Nov 9 [cited 2023 Dec 9]; Available from: https://www.nature.com/articles/s41562-023-01749-9
- 20. Lo B, Field MJ, Institute of Medicine (U.S.), editors. Conflict of interest in medical research, education, and practice. Washington, D.C: National Academies Press; 2009. 414 p.
- 389 21. Nosek BA, Alter G, Banks GC, Borsboom D, Bowman S, Breckler S, et al. Transparency and openness promotion (TOP) guidelines. 2016;
- 391 22. Fišar M, Greiner B, Huber C, Katok E, Ozkes A, Collaboration MSR. Reproducibility in
 392 Management Science [Internet]. Open Science Framework; 2023 Nov [cited 2023 Dec 9].
 393 Available from: https://osf.io/mydzv
- 394 23. Wallach JD, Boyack KW, Ioannidis JPA. Reproducible research practices, transparency, and open access data in the biomedical literature, 2015–2017. Dirnagl U, editor. PLOS Biol. 2018 Nov 20;16(11):e2006930.

- 24. Page MJ, Nguyen PY, Hamilton DG, Haddaway NR, Kanukula R, Moher D, et al. Data and code availability statements in systematic reviews of interventions were often missing or inaccurate: a content analysis. J Clin Epidemiol. 2022 Jul;147:1–10.
- 25. Dunn AG, Coiera E, Mandl KD, Bourgeois FT. Conflict of interest disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency. Res Integr Peer Rev. 2016 Dec;1(1):1.
- 26. Sofi-Mahmudi A, Raittio E, Khademioore S, Uribe SE, Moher D. Data Quality in 59 Fields of Clinical Medicine According to the FAIR Principles: Protocol for a Meta-Research Study. 2024 [cited 2024 Apr 11]; Available from: https://osf.io/e6stx/
- 27. Sofi-Mahmudi A, Raittio E, Khazaei Y, Ashraf J, Schwendicke F, Uribe SE, et al. COVID-19-related research data availability and quality according to the FAIR principles: A meta-research study [Internet]. 2023 [cited 2024 Apr 11]. Available from: http://biorxiv.org/lookup/doi/10.1101/2023.11.14.566998
- 28. Menke J, Roelandse M, Ozyurt B, Martone M, Bandrowski A. The Rigor and Transparency Index
 Quality Metric for Assessing Biological and Medical Science Methods. iScience. 2020
 Nov;23(11):101698.

